[go: up one dir, main page]

WO2025143279A1 - Schéma combiné de décitabine et de belotécan pour prévenir ou traiter le cancer de l'ovaire - Google Patents

Schéma combiné de décitabine et de belotécan pour prévenir ou traiter le cancer de l'ovaire Download PDF

Info

Publication number
WO2025143279A1
WO2025143279A1 PCT/KR2023/021623 KR2023021623W WO2025143279A1 WO 2025143279 A1 WO2025143279 A1 WO 2025143279A1 KR 2023021623 W KR2023021623 W KR 2023021623W WO 2025143279 A1 WO2025143279 A1 WO 2025143279A1
Authority
WO
WIPO (PCT)
Prior art keywords
decitabine
belotecan
acceptable salt
pharmaceutically acceptable
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2023/021623
Other languages
English (en)
Korean (ko)
Inventor
김희승
박수진
이승미
송권화
임화선
박선우
박원형
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dreampac Corp
Precision Medicine For Peritoneal Metastasis Cooperative
Sungkyunkwan University
Korea University Research and Business Foundation
SNU R&DB Foundation
Gyeongsang National University GNU
Industry Academic Cooperation Foundation of Keimyung University
Seoul National University Hospital
Original Assignee
Dreampac Corp
Precision Medicine For Peritoneal Metastasis Cooperative
Sungkyunkwan University
Korea University Research and Business Foundation
Seoul National University R&DB Foundation
Gyeongsang National University GNU
Industry Academic Cooperation Foundation of Keimyung University
Seoul National University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dreampac Corp, Precision Medicine For Peritoneal Metastasis Cooperative, Sungkyunkwan University, Korea University Research and Business Foundation, Seoul National University R&DB Foundation, Gyeongsang National University GNU, Industry Academic Cooperation Foundation of Keimyung University, Seoul National University Hospital filed Critical Dreampac Corp
Publication of WO2025143279A1 publication Critical patent/WO2025143279A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Ovarian cancer is one of the most deadly gynecological cancers worldwide. In the United States, the number of cancer deaths due to ovarian cancer in 2019 was estimated at 13,980 (4.9% of female cancer deaths), and the incidence of ovarian cancer is gradually increasing in Korea. However, most ovarian cancers are diagnosed at a difficult-to-treat stage due to the lack of effective diagnostic methods for ovarian cancer, resulting in high recurrence and mortality rates.
  • Belotecan has been used as a compound with some degree of effectiveness against ovarian cancer, but there has been an increasing need to develop a more effective drug.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing, improving or treating ovarian cancer comprising the combination.
  • Another object of the present invention is to provide a pharmaceutical kit for preventing, improving or treating ovarian cancer comprising the above combination.
  • Another object of the present invention is to provide a method for preventing, improving or treating ovarian cancer, comprising the step of administering and/or using the combination, pharmaceutical composition or pharmaceutical kit to a subject in need thereof.
  • Another object of the present invention is to provide a health functional food composition for preventing or improving ovarian cancer, comprising decitabine or a food-related acceptable salt thereof and belotecan or a food-related acceptable salt thereof as active ingredients.
  • Another object of the present invention is to provide a feed composition for preventing or improving ovarian cancer, comprising decitabine or a feed-based acceptable salt thereof and belotecan or a feed-based acceptable salt thereof as active ingredients.
  • Another object of the present invention is to provide a composition for inhibiting ovarian cancer metastasis, comprising decitabine or a pharmaceutically acceptable salt thereof and belotecan or a pharmaceutically acceptable salt thereof as active ingredients.
  • Another object of the present invention is to provide a method for preventing, improving or treating ovarian cancer, comprising the step of co-administering and/or co-using a composition comprising a pharmaceutically effective amount of decitabine, or a pharmaceutically acceptable salt or solvate thereof; and belotecan, or a pharmaceutically acceptable salt or solvate thereof, to a subject in need thereof.
  • Another object of the present invention is to provide a use of the combination, pharmaceutical composition, or pharmaceutical kit for preventing, ameliorating or treating ovarian cancer, and/or for the manufacture of a medicament for preventing, ameliorating or treating ovarian cancer.
  • Figure 1 shows information on five ovarian cancer cell lines. Specifically, it shows the histological type, origin, and mutation type of TP53 and ARID1A in each cell line.
  • Figure 7 shows flow cytometric analysis of lymphocytes in the spleen of mice after decitabine treatment.
  • Decitabine (0.25 mg/kg) was administered intraperitoneally 5 times on day 1, 6 times on day 2, and 10 times on day 2.
  • SSC-A/FSC-A contour plots show gating according to lymphocyte size. Cells were gated on FSC-A/FSC-H to remove doublets.
  • Statistical significance is indicated by asterisks (***P ⁇ 0.001, **P ⁇ 0.01, *P ⁇ 0.05).
  • kits for the prevention or treatment of ovarian cancer comprising (i) decitabine, or a pharmaceutically acceptable salt or solvate thereof; and (ii) belotecan, or a pharmaceutically acceptable salt or solvate thereof, as active ingredients.
  • the "kit” in the present invention may include a combination or composition according to the present invention for co-administration of decitabine, or a pharmaceutically acceptable salt or solvate thereof; and belotecan, or a pharmaceutically acceptable salt or solvate thereof.
  • the kit of the present invention may include individual preparations of decitabine, or a pharmaceutically acceptable salt or solvate thereof; and belotecan, or a pharmaceutically acceptable salt or solvate thereof, each of which is formulated as a single preparation.
  • the kit may additionally include a material necessary for co-administration of the two substances. However, it is not necessarily limited thereto.
  • Another aspect of the present invention is a method for preventing, improving or treating ovarian cancer, comprising administering to a subject in need thereof and/or using together a composition comprising a pharmaceutically effective amount of decitabine, or a pharmaceutically acceptable salt or solvate thereof; and a composition comprising belotecan, or a pharmaceutically acceptable salt or solvate thereof.
  • compositions comprising a pharmaceutically effective amount of decitabine, or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutical composition comprising belotecan, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical kit for the prevention, amelioration or treatment of ovarian cancer, and/or for the manufacture of a medicament for the prevention, amelioration or treatment of ovarian cancer.
  • Another aspect of the present invention provides a pharmaceutical composition for inhibiting metastasis of ovarian cancer, comprising a composition comprising a pharmaceutically effective amount of decitabine, or a pharmaceutically acceptable salt or solvate thereof; and belotecan, or a pharmaceutically acceptable salt or solvate thereof.
  • a composition comprising decitabine, or a pharmaceutically acceptable salt or solvate thereof; and belotecan, or a pharmaceutically acceptable salt or solvate thereof, for the prevention and treatment of ovarian cancer, as described above in the other embodiments.
  • Another aspect of the present invention is a health functional food composition for preventing or improving ovarian cancer, comprising decitabine or a food-chemically acceptable salt thereof and belotecan or a food-chemically acceptable salt thereof as active ingredients.
  • the food composition of the present invention includes forms such as pills, powders, granules, infusions, tablets, capsules or liquids, and foods to which the composition of the present invention can be added include, for example, various foods, such as beverages, gum, tea, vitamin complexes, and health supplements.
  • natural carbohydrates examples include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, etc.; and polysaccharides such as dextrin, cyclodextrin, etc., common sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc.
  • natural flavoring agents e.g., rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.
  • it may contain fruit pulp for the production of natural fruit juice and fruit juice drinks and vegetable drinks. These ingredients may be used independently or in combination.
  • the above functional food is the same term as food for special health use (FoSHU), and means a food with high medical and healthcare effects that is processed to efficiently exhibit a bioregulatory function in addition to nutritional supply.
  • “functionality” means regulating nutrients for the structure and function of the human body or obtaining a useful effect for health purposes such as physiological effects.
  • the food of the present invention can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art during the manufacturing process.
  • the formulation of the food can be manufactured without limitation as long as it is a formulation recognized as food.
  • the above feed composition may contain, in addition to decitabine and belotecan, known carriers, stabilizers, or additives acceptable for pharmaceutical, food, or feed use.
  • binders, emulsifiers, and preservatives may be added to prevent quality deterioration, and amino acids, vitamins, enzymes, flavoring agents, non-protein nitrogen compounds, silicates, buffers, extractants, oligosaccharides, and the like may be added to the feed to increase utility.
  • feed mixers may be additionally included, but are not limited thereto.
  • the feed composition may contain various nutrients such as vitamins, amino acids, and minerals, antioxidants, and other additives, as needed, and may be in an appropriate form such as powder, granules, pellets, or suspension.
  • the feed composition of the present invention may be supplied alone or mixed with feed to a single animal.
  • the feed of the present invention is not particularly limited, and is not limited as long as it is for animals such as dogs, cats, horses, and cows, and any feed may be used, including powdered feed, solid feed, dry feed, wet feed, moist pellet feed, dry pellet feed, EP (Extruder Pellet) feed, and raw feed.
  • a composition comprising decitabine, or a pharmaceutically acceptable salt or solvate thereof; and belotecan, or a pharmaceutically acceptable salt or solvate thereof, and for ovarian cancer as described above in the other embodiments.
  • Belotecan (Camtobel®) was supplied by Chong Kun Dang Pharmaceutical Co., Ltd. (Seoul, Korea) and decitabine (Decilid®) was supplied by Samyang Biopharm (Seongnam, Korea).
  • Topotecan hydrochloride hydrate (Cat. T2705) was purchased from Sigma-Aldrich (St. Louis, USA).
  • stock solutions of belotecan (2 mM), topotecan (5 mM), and decitabine (20 mM) were prepared by dissolving them in UPW.
  • ID8 cells were maintained in DMEM/high glucose supplemented with 4% FBS, 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 5 ng/ml sodium selenite, and 1% penicillin/streptomycin. All cells were grown at 37°C in a 5% CO 2 incubator, and monolayer cells were cultured to 70-80% confluence for use in experiments.
  • Cell viability was determined using the MTT detection kit (Cat. 11465007001, Roche). For viability evaluation, cells were seeded in 96-well culture plates, and various concentrations of topotecan, belotecan, and decitabine were treated for 48 h. MTT labeling reagent was added to the cells and incubated for 4 h. After that, the solubilization solution was added to the cells without removing the culture medium. After overnight incubation at 37°C, the reaction wells were detected by colorimetric analysis using a spectrophotometer.
  • MTT detection kit Cat. 11465007001, Roche.
  • mice Four-week-old female C57BL/6 (J) mice were purchased from DBL (Incheon, Korea) and housed for 1 week for acclimatization. All mice were housed in a controlled environment (12/12 h light/dark cycle, 23°C, 50% humidity) and had free access to food and water.
  • Example 8 Flow cytometric analysis of lymphocytes from mouse spleen
  • Example 1 Confirmation of cell viability effects of belotecan and topotecan in five types of ovarian cancer cell lines
  • ovarian cancer cell lines including ES-2, SKOV3, TOV21G, and TOV112D and mouse ovarian cancer cell line ID8 were used. All cell lines have different mutation types of TP53 and ARID1A, as shown in Fig. 1.
  • belotecan was found to be more effective in impairing cell viability than topotecan at all experimental doses in ES-2 (Fig. 2A), TOV-21G (Fig. 2C), and ID8 (Fig. 2E) cell lines.
  • TOV-112D cells both belotecan and topotecan only slightly affected cell viability at concentrations below 5 ⁇ M.
  • belotecan reduced TOV-112D cell viability more significantly than topotecan (Fig. 2D).
  • SKOV3 cell line the decrease in cell viability was almost the same when belotecan and topotecan were treated (Fig. 2B).
  • Example 3 Based on the results of Example 3, we sought to confirm the induction of apoptosis in human ovarian cancer cell lines after treatment with belotecan and 10 ⁇ M decitabine.
  • TNF did not show statistical changes in ES-2 (Fig. 6A) and was significantly increased by up to 1.71-fold (P ⁇ 0.01) and 1.18-fold (P ⁇ 0.05) in SKOV3 and TOV-21G cells by decitabine treatment (Figs. 6B and 6C).
  • decitabine decreased the transcription level of TNF by approximately 0.49-fold (P ⁇ 0.01) in TOV-112D (Fig. 6D).
  • mice To determine the optimal injection frequency and administration time to verify the immunomodulatory effect of decitabine, a preliminary experiment was conducted on mice. Specifically, decitabine (0.25 mg/kg) was administered via intraperitoneal injection five times a day or six or ten times every other day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un régime combiné de décitabine et de belotécan pour prévenir ou traiter le cancer de l'ovaire, et fournit une composition pharmaceutique pour prévenir ou traiter le cancer de l'ovaire, la composition pharmaceutique étant caractérisée en ce qu'elle contient de la décitabine ou un sel ou solvate pharmaceutiquement acceptable de celle-ci comme principe actif, la composition pharmaceutique étant administrée en combinaison avec du belotécan ou un sel ou solvate pharmaceutiquement acceptable de celui-ci.
PCT/KR2023/021623 2023-12-26 2023-12-26 Schéma combiné de décitabine et de belotécan pour prévenir ou traiter le cancer de l'ovaire Pending WO2025143279A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2023-0191683 2023-12-26
KR1020230191683A KR20250100273A (ko) 2023-12-26 2023-12-26 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법

Publications (1)

Publication Number Publication Date
WO2025143279A1 true WO2025143279A1 (fr) 2025-07-03

Family

ID=96219204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/021623 Pending WO2025143279A1 (fr) 2023-12-26 2023-12-26 Schéma combiné de décitabine et de belotécan pour prévenir ou traiter le cancer de l'ovaire

Country Status (2)

Country Link
KR (1) KR20250100273A (fr)
WO (1) WO2025143279A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170054997A (ko) * 2015-11-09 2017-05-18 서울대학교산학협력단 데시타빈 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골수유래억제세포 저해용 조성물
KR20190019489A (ko) * 2017-08-18 2019-02-27 동화약품주식회사 Rip3 발현 촉진제 또는 활성화제를 포함하는 항암 보조용 조성물
KR20230024402A (ko) * 2020-06-14 2023-02-20 글리코미메틱스, 인크. E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법
US20230263818A1 (en) * 2020-02-25 2023-08-24 Otsuka Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170054997A (ko) * 2015-11-09 2017-05-18 서울대학교산학협력단 데시타빈 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골수유래억제세포 저해용 조성물
KR20190019489A (ko) * 2017-08-18 2019-02-27 동화약품주식회사 Rip3 발현 촉진제 또는 활성화제를 포함하는 항암 보조용 조성물
US20230263818A1 (en) * 2020-02-25 2023-08-24 Otsuka Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms
KR20230024402A (ko) * 2020-06-14 2023-02-20 글리코미메틱스, 인크. E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK SOO JIN, PARK WONHYOUNG, LIM WHASUN, LEE SEUNGMEE , SONG GWONHWA, PARK SUNWOO, KIM HEE SEUNG: "EP014/#682 EFFECT OF DECITABINE COMBINED WITH BELOTECAN ON T-CELL MEDIATED IMMUNITY IN OVARIAN CANCER", INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 33, no. 4, 1 November 2023 (2023-11-01), US , pages A89 - A89, XP093329328, ISSN: 1048-891X, DOI: 10.1136/ijgc-2023-IGCS.145 *

Also Published As

Publication number Publication date
KR20250100273A (ko) 2025-07-03

Similar Documents

Publication Publication Date Title
KR100829875B1 (ko) 항암제로서의 병용 의약 조성물
WO2015130109A1 (fr) Composition pharmaceutique pour le traitement du cancer contenant du gossypol et de la phénformine en tant que principes actifs
WO2020262974A1 (fr) Composition pharmaceutique pour le traitement de la leucémie myéloïde aiguë contenant un inhibiteur de flt3 et des agents de chimiothérapie
WO2021060945A1 (fr) Microbe intestinal humain anaérobie obligatoire pour le traitement du cancer, et son utilisation
WO2015026112A1 (fr) Composition contenant un composé monoacétyldiglycéride en tant que principe actif pour l'inhibition du cancer du sang ou de métastase
WO2021230600A1 (fr) Composition anticancéreuse comprenant un médicament anticancéreux métabolique
WO2022103138A1 (fr) Composition pour la prévention ou le traitement du cancer comprenant du bifidobacterium longum rapo (kctc13773bp)
WO2017078405A9 (fr) Composition pharmaceutique pour le traitement du cancer du poumon comprenant un composé à base de glucocorticoïde
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2018155921A1 (fr) Composition pharmaceutique destinée à prévenir et à traiter le cancer du pancréas, contenant du gossypol et de la phénformine à titre de principes actifs
WO2020141828A2 (fr) Compositions anticancéreuses comprenant des inhibiteurs de points de contrôle immunitaires
WO2025143279A1 (fr) Schéma combiné de décitabine et de belotécan pour prévenir ou traiter le cancer de l'ovaire
WO2019035522A1 (fr) Composition pour prévenir ou traiter le cancer, contenant un dérivé à base de triazolopyridine comme principe actif
WO2015199454A1 (fr) Composition médicamenteuse résistante aux inhibiteurs du récepteur de la tyrosine kinase, contenant de l'acide 3,4,5-trihydroxybenzoïque, un dérivé de celui-ci ou un sel de celui-ci en tant que principe actif
WO2016072692A2 (fr) Composition pour prévenir ou traiter la mucosite, comprenant du necrox en tant que principe actif
US10266510B2 (en) Antimicrobial and cytotoxic compounds and methods for treating cancer, a bacterial infection, and/or a fungal infection
WO2023163539A1 (fr) Utilisation d'un nouveau dérivé de pomalidomide pour traiter des maladies cérébrales
WO2024039164A1 (fr) Composition pour la prévention, l'amélioration ou le traitement du cancer comprenant de la steppogénine en tant que principe actif
KR101718380B1 (ko) 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물
WO2022025709A1 (fr) Utilisation préventive, de soulagement ou thérapeutique de composé thiophène 2,3,5-substitué contre une tumeur stromale gastro-intestinale
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
WO2023113129A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement d'un cancer du sang comprenant un inhibiteur de surf4
WO2016148448A2 (fr) Composition de vaccin contre le cancer et kit
WO2025225833A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de cancers résistants aux médicaments anticancéreux, contenant du tériflunomide en tant que principe actif
WO2025225832A1 (fr) Composition pharmaceutique pour prévention ou traitement de cancers résistants aux agents anticancéreux, contenant de la trovafloxacine comme principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23963244

Country of ref document: EP

Kind code of ref document: A1